Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 7:32 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 290 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Sweat Clear all
Completed No phase listed Observational

Wound Etiology and Healing Study

NCT01352078
View directory record Official record
Conditions
Wounds, Hidradenitis Suppurativa, Hidradenitis, Acne Inversa
Interventions
Not listed
Lead sponsor
George Washington University
Other
Eligibility
18 Years to 99 Years
Enrollment
743 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2022
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jul 27, 2022 · Synced Oct 30, 2026, 7:32 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Treatment of Hidradenitis Suppurativa Using Etanercept

NCT00949546
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
etanercept
Drug
Lead sponsor
Penn State University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 24, 2017 · Synced Oct 30, 2026, 7:32 PM EDT
Completed Phase 2 Interventional Results available

Hidradenitis Suppurativa Phase 2b Study of Izokibep

NCT05355805
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Izokibep, Placebo to izokibep
Drug
Lead sponsor
ACELYRIN Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
20
States / cities
Birmingham, Alabama • Encino, California • Fountain Valley, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2025 · Synced Oct 30, 2026, 7:32 PM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Efficacy and Tolerability of a Fractional Ablative Erbium Laser for Axillary Scarring for Hidradenitis Suppurativa Patients

NCT05470322
View directory record Official record
Conditions
Hidradenitis Suppurativa, Scarring
Interventions
Er: YAG laser
Device
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Elmsford, New York
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Oct 30, 2026, 7:32 PM EDT
Completed Phase 2 Interventional Results available

Efficacy, Safety, and Pharmacokinetics Study of CJM112 in Hidradenitis Suppurativa Patients

NCT02421172
View directory record Official record
Conditions
Hidradenitis Suppurativa (Acne Inversa)
Interventions
CJM112, Placebo
Biological · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
Not listed
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
9
States / cities
Los Angeles, California • Ormond Beach, Florida • Tampa, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2022 · Synced Oct 30, 2026, 7:32 PM EDT
Completed Phase 2 Interventional Results available

A Safety and Efficacy Study of BBI-4000 in Subjects With Axillary Hyperhidrosis

NCT02336503
View directory record Official record
Conditions
Hyperhidrosis
Interventions
BBI-4000 Gel, 5%, BBI-4000 Gel, 10%, BBI-4000 Gel, 15%, Vehicle
Drug
Lead sponsor
Botanix Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
189 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
12
States / cities
Fremont, California • San Diego, California • Aventura, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2023 · Synced Oct 30, 2026, 7:32 PM EDT
Completed No phase listed Observational

Impact of Hidradenitis Suppurativa on Quality of Life Functions

NCT03288337
View directory record Official record
Conditions
Hidradenitis Suppurativa, Quality of Life
Interventions
Not listed
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years to 99 Years
Enrollment
400 participants
Timeline
2015 – 2022
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jan 20, 2023 · Synced Oct 30, 2026, 7:32 PM EDT
Completed Phase 2 Interventional

Anifrolumab for Hidradenitis Suppurativa

NCT06374212
View directory record Official record
Conditions
Hidradenitis Suppurativa, Acne Inversa, Hidradenitis
Interventions
Anifrolumab
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Oct 30, 2026, 7:32 PM EDT
Terminated Phase 2 Interventional

Evaluate Safety and Pharmacokinetics of INF904 in Subjects With Moderate to Severe Chronic Spontaneous Urticaria or Hidradenitis Suppurativa

NCT06555328
View directory record Official record
Conditions
Chronic Urticaria, Idiopathic, Hidradenitis, Hidradenitis Suppurativa
Interventions
CSU lower dose treatment, CSU high dose treatment, CSU non responders IgE - high dose treatment, HS low dose treatment, HS medium dose treatment, HS high dose treatment
Drug
Lead sponsor
InflaRx GmbH
Industry
Eligibility
18 Years to 99 Years
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
9
States / cities
Fountain Valley, California • North Miami Beach, Florida • Tampa, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Oct 30, 2026, 7:32 PM EDT
Completed Phase 4 Interventional Results available

Safety and Efficacy of Adalimumab (Humira) for Hidradenitis Suppurativa (HS) Peri-Surgically

NCT02808975
View directory record Official record
Conditions
Hidradenitis Suppurativa (HS)
Interventions
Placebo, Adalimumab
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
9
States / cities
Beverly Hills, California • Encino, California • Irvine, California + 6 more
Source: ClinicalTrials.gov public record
Updated May 14, 2020 · Synced Oct 30, 2026, 7:32 PM EDT
Completed Not applicable Interventional

Trial Comparing Efficacy of Treatments for Hidradenitis Suppurativa

NCT01063270
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Clindamycin & Rifampin, Clindamycin + Rifampin along with NdYag Laser treatment
Drug · Procedure
Lead sponsor
Henry Ford Health System
Other
Eligibility
16 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 22, 2022 · Synced Oct 30, 2026, 7:32 PM EDT
Completed Phase 3 Interventional Results available

Long-term Safety Study of Glycopyrronium in Subjects With Primary Axillary Hyperhidrosis

NCT02553798
View directory record Official record
Conditions
Hyperhidrosis
Interventions
Glycopyrronium Topical Wipes
Drug
Lead sponsor
Journey Medical Corporation
Industry
Eligibility
9 Years and older
Enrollment
564 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
40
States / cities
Mobile, Alabama • Rogers, Arkansas • Encinitas, California + 37 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2021 · Synced Oct 30, 2026, 7:32 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Treatment of Hidradenitis Suppurativa With Eth 755nm Alexandrite Laser

NCT03054155
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Alexandrite Laser
Device
Lead sponsor
Wayne State University
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2022
U.S. locations
1
States / cities
Dearborn, Michigan
Source: ClinicalTrials.gov public record
Updated May 16, 2023 · Synced Oct 30, 2026, 7:32 PM EDT
Recruiting Phase 2 Interventional

A Study of Zasocitinib in Adults With Hidradenitis Suppurativa

NCT07244263
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Zasocitinib (Dose A), Placebo
Drug · Other
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
15
States / cities
Scottsdale, Arizona • Fort Smith, Arkansas • Fountain Valley, California + 12 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2026 · Synced Oct 30, 2026, 7:32 PM EDT
Completed Not applicable Interventional Results available

Evaluation of 1440nm Laser vs. Botulinum Toxin or miraDry® Microwave For Treatment of Axillary Hyperhidrosis

NCT01811004
View directory record Official record
Conditions
Hyperhidrosis
Interventions
miraDry, Nd:YAG Laser, Botox®
Device
Lead sponsor
Cynosure, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Pasadena, California
Source: ClinicalTrials.gov public record
Updated Jan 22, 2021 · Synced Oct 30, 2026, 7:32 PM EDT
Recruiting Phase 3 Interventional

Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib

NCT06855498
View directory record Official record
Conditions
Hidradenitis Suppurativa (HS)
Interventions
povorcitinib
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
94
States / cities
Birmingham, Alabama • Montgomery, Alabama • Phoenix, Arizona + 72 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2026 · Synced Oct 30, 2026, 7:32 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional

A Study Evaluating BFB759 in Moderate to Severe Hidradenitis Suppurativa

NCT07287644
View directory record Official record
Conditions
Hidradenitis Suppurativa (HS)
Interventions
BFB759, Placebo for BFB759
Biological · Other
Lead sponsor
Bluefin Biomedicine, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
35
States / cities
Phoenix, Arizona • Encino, California • Huntington Beach, California + 32 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 30, 2026, 7:32 PM EDT
Completed Phase 1 Interventional

Hyperhidrosis in Patients With Amputations-Botox

NCT03236012
View directory record Official record
Conditions
Hyperhidrosis
Interventions
Botulinum Toxin Type A (Botox)
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
2
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Oct 17, 2022 · Synced Oct 30, 2026, 7:32 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

NBA G-League Sweat Testing Study: Validity of the Gx Sweat Patch in Measuring Sweating Rate and Sweat Chloride Concentration During On-court Training With Basketball Players

NCT04679532
View directory record Official record
Conditions
Sweat Analysis
Interventions
Gx sweat patch, Reference sweat patch
Other
Lead sponsor
PepsiCo Global R&D
Industry
Eligibility
18 Years to 40 Years · Male only
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Walnut Creek, California
Source: ClinicalTrials.gov public record
Updated Jun 23, 2022 · Synced Oct 30, 2026, 7:32 PM EDT
Active, not recruiting Phase 1 Interventional

Study of Single Doses of SBT777101 in Subjects With Hidradenitis Suppurativa

NCT06361836
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
SBT777101
Biological
Lead sponsor
Sonoma Biotherapeutics, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
6
States / cities
Boston, Massachusetts • Minneapolis, Minnesota • St Louis, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2026 · Synced Oct 30, 2026, 7:32 PM EDT
Completed No phase listed Observational Results available

: TRANSITION: An Observational Study of Transition From Lumacaftor/Ivacaftor to Tezacaftor/Ivacaftor (Tez/Iva)

NCT03445793
View directory record Official record
Conditions
Cystic Fibrosis (CF)
Interventions
Not listed
Lead sponsor
National Jewish Health
Other
Eligibility
12 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 23, 2024 · Synced Oct 30, 2026, 7:32 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Single and Multiple Ascending Dose Trial of KT-474 in Healthy Adult Volunteers and Patients With Atopic Dermatitis (AD) or Hidradenitis Suppurativa (HS)

NCT04772885
View directory record Official record
Conditions
Healthy Volunteer, Atopic Dermatitis, Hidradenitis Suppurativa
Interventions
KT-474/Placebo, KT-474
Drug
Lead sponsor
Kymera Therapeutics, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
154 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
14
States / cities
Phoenix, Arizona • Sun City West, Arizona • Boynton Beach, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2022 · Synced Oct 30, 2026, 7:32 PM EDT
Recruiting Phase 2 Interventional

ORKA-002 Versus Placebo in Participants With Moderate-to-Severe Hidradenitis Suppurativa

NCT07783542
View directory record Official record
Conditions
Hidradenitis Suppurativa (HS)
Interventions
ORKA-002, Placebo
Drug · Other
Lead sponsor
Oruka Therapeutics, Inc.
Industry
Eligibility
18 Years to 79 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
20
States / cities
Birmingham, Alabama • Fountain Valley, California • Los Angeles, California + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2026 · Synced Oct 30, 2026, 7:32 PM EDT
Completed Phase 2 Interventional Results available

To Assess the Efficacy and Safety of INCB054707 in Participants With Hidradenitis Suppurativa

NCT04476043
View directory record Official record
Conditions
Hidradenitis Suppurativa, Acne Inversa
Interventions
INCB054707, Placebo
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years to 75 Years
Enrollment
209 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
25
States / cities
Hoover, Alabama • Gilbert, Arizona • Phoenix, Arizona + 21 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2025 · Synced Oct 30, 2026, 7:32 PM EDT